Skip to main content

Table 2 Summary of the pooled HR

From: The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis

  Studies (N) HR (95%CI) I 2 P value
   OS PFS OS without CC3 PFS without CC3 OS PFS OS withoutCC3 PFS withoutCC3 OS PFS OS withoutCC3 PFS withoutCC3
HIPEC group vs non-HIPEC group 13 0.54 (0.45-0.66) 0.45(0.32-0.62) 0.51(0.42-0.63) 0.41(0.32-0.52) 48% 60% 39% 10% <0.0001 <0.0001 <0.0001 <0.0001
Subgroup
Primary ovarian cancer 6 0.59(0.46-0.75) 0.41(0.32-0.54) _ _ 34% 32% _ _ <0.0001 <0.0001 _ _
Recurrent ovarian cancer 5 0.45(0.24 to 0.83) 0.55(0.27 to 1.11) 0.38(0.25 to 0.56) 0.41(0.27 to 0.62) 60% 77% 0 0 0.01 0.09 <0.0001 <0.0001
Stage III-IV 5 0.64(0.50 to 0.82) 0.36(0.20 to 0.65) _ _ 0 66% - - 0.0004 0.0007 - -
Interval CRS plus HIPEC 2 0.61(0.45 to 0.83) 0.29(0.1 to 0.86) - - 50% 80% - - 0.002 0.03 - -
Primary CRS plus HIPEC 10 0.47(0.37 to 0.61) 0.52(0.41 to 0.65) 0.43(0.33 to 0.55) 0.43(0.33 to 0.55) 50% 50% 28% 0 <0.0001 <0.0001 <0.0001 <0.0001